In Dec 2019, a mysterious virus emerged from China and today thousands of coronavirus cases are being reported in different countries of the world. Coronavirus is associated with a series of health conditions like pneumonia, common cold, and severe acute respiratory syndrome (SARS) but scientists are still unable to find any treatment and vaccine against this virus.
This new study finds that the coronavirus outbreak in the Wuhan City of China has spread alerts in all the agencies across the whole world. To get out people from the coronavirus fear, the National Institute of Health (NIH) is trying to discover vaccines against coronavirus and it is hoped that the treatment will begin within three months.
The researchers are making efforts to fight emerging coronavirus. These efforts may include research and developments by using modern technologies. Many biotech firms are unable to offer any treatment but may some firms find the instant application to the coronavirus.
The companies that will benefit directly from the new approaches are Oncholytics Biotech Inc., Inovio pharmaceutical, Inc., and TrovaGene Inc. Aethlon Medical, Inc., is a medical technology company that addresses the unmet needs in biodefence and health in the whole world.
The patented Aethlon Homopurifier is developed by Aethlon Medical Inc. It is a clinical-stage immunotherapeutic device. With the help of this device exosomes and life-threatening viruses are removed from the circulatory system.
Many infectious diseases like Hepatitis C, Ebola virus, and the HIV deadly viruses can be treated by using this device. Aethlon has also developed TauSome that has an exosomal biomarker. This biomarker helps to diagnose the chronic traumatic encephalopathy in living organisms.
Some researchers consider that coronavirus is not much fatal as Severe Acute Respiratory Syndrome (SARS). The symptoms of coronavirus are cough, fever, congestion of lungs, and sore throat. Pneumonia is the most advanced stage found in some individuals and elderly patients with existing problems.
Antibiotics can kill bacteria but not viruses. That’s why no vaccines are available against Wuhan coronavirus. The director of CDCs, a virus institute in China, Xu Wenbo finds that if the genetic information is available than the vaccines can be made much faster against any virus.
In the case of coronavirus, the virus has been isolated and the strain has been selected means genetic information is available. This is the reason that NIH hopes to begin the treatment within three months.
The director of the US National Institute of Allergy, Anthony Fauci, considers that if the researchers get succeeded in starting the treatment within three months, it will be the fastest gene sequence to start the human testing in the history of the agency.
All the biotech companies are trying to find the treatments against all the emerging viruses like the 2019-nCoV and coronavirus. The National Institute of Health (NIH) is collaborating with many other companies to come up with solutions and hopes to find the possible treatments for coronavirus as soon as three months.